ANNOUNCEMENT

Save $300 on MedCity CONVERGE Healthcare Innovation Summit July 9-10 in Philadelphia. Earlybird rate ends May 20.

Topic: Fidelity Biosciences

Orphan drug firm with potential first treatment for HIBM raises $15 million

Orphan drug firm with potential first treatment for HIBM raises $15 million

August 14, 2012 12:01 pm by | 0 Comments

Ultragenyx is developing a sialic acid replacement therapy for treatment of the rare, progressive neuromuscular disease hereditary inclusion body myopathy that causes muscles to waste away. ... Read more
NeuroTherapeutics Pharma closes $43M Series B round

NeuroTherapeutics Pharma closes $43M Series B round

May 20, 2010 11:41 am by | 0 Comments

NeuroTherapeutics Pharma Inc., which is developing drugs to combat central nervous system disorders, has closed a $43 million Series B round of funding that will take it through multiple Phase ... Read more